Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 6 of 100, showing 5 Applications out of 500 total, starting on record 26, ending on 30

# Protocol No Study Title Investigator(s) & Site(s)

26.

ECCT/24/06/07   Gates MRI TBV02-301
    A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults.   
Principal Investigator(s)
1. Charity Wambui Kanyoro
Site(s) in Kenya
1. Moi University Clinical Research Centre (Uasin Gishu county)
 
View

27.

ECCT/24/06/06   EDE Scanner Study
    A non-interventional clinical validation study of the Exponential Deep Examination (EDE) scanner in the detection of human immunodeficiency virus (HIV), tuberculosis (TB) and malaria.   
Principal Investigator(s)
1. Bernhards Ogutu
2. Lucas Tina
3. VIDELIS NDUBA
Site(s) in Kenya
1. VICTORIA BIOMEDICAL RESEARCH INSTITUTE (Kisumu county)
2. KEMRI/CRDR Siaya Clinical Trials Annex (Siaya county)
3. Ahero Clinical Trials Unit (Kisumu county)
 
View

28.

ECCT/24/06/05   SII-qHPV Vaccine Study
    A Phase-3b, partially double-blind, randomized, multi-country clinical study to evaluate the immunogenicity, safety, and reactogenicity of SIIPL qHPV vaccine (CERVAVAC®) in women living with HIV aged 15-25 years.   
Principal Investigator(s)
1. Nelly Rwamba Mugo
Site(s) in Kenya
1. KEMRI-CCR PHRD Thika (Kiambu county)
2. KEMRI - CCR Nairobi (Nairobi City county)
 
View

29.

ECCT/24/06/04   ALNASA
    A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE       
Principal Investigator(s)
1. Jacqueline Mirera
Site(s) in Kenya
1. Clinical Research Health Network (CREA-N) (Machakos county)
 
View

30.

ECCT/24/06/03   PEARL RSVt Vaccine Study
    Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL   
Principal Investigator(s)
1. Dr Walter Otieno
Site(s) in Kenya
1. KEMRI-USAMRD-A Kombewa Clinical Research Centre (Kisumu county)
 
View